VERONA PHARMA P/S (VRNA) Downgraded by Zacks Investment Research

VERONA PHARMA P/S (NASDAQ:VRNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. “

A number of other equities analysts have also weighed in on VRNA. Wedbush set a $56.00 price objective on shares of VERONA PHARMA P/S and gave the stock a “buy” rating in a report on Tuesday, August 7th. Jefferies Financial Group restated a “buy” rating and issued a $26.00 price objective on shares of VERONA PHARMA P/S in a report on Friday, August 10th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $31.33.

NASDAQ VRNA traded down $0.35 during mid-day trading on Friday, reaching $11.75. The stock had a trading volume of 6,664 shares, compared to its average volume of 1,417. VERONA PHARMA P/S has a 1 year low of $10.44 and a 1 year high of $25.55. The firm has a market cap of $163.78 million, a P/E ratio of -4.88 and a beta of -1.31.

VERONA PHARMA P/S (NASDAQ:VRNA) last announced its quarterly earnings data on Tuesday, August 7th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $1.20. Equities research analysts predict that VERONA PHARMA P/S will post -2.32 earnings per share for the current year.

VERONA PHARMA P/S Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Recommended Story: What is a Tariff?

Get a free copy of the Zacks research report on VERONA PHARMA P/S (VRNA)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for VERONA PHARMA P/S (NASDAQ:VRNA)

Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with's FREE daily email newsletter.

Leave a Reply